Sugi Predict

Sugi Predict / Compounds / SCHEMBL650333

SCHEMBL650333

SCHEMBL650333

c1ccc(CN2CCC(N3CCOCC3)CC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 4/20 0.59
▸ DRD4 P21917 4/20 0.59
▸ DRD3 P35462 4/20 0.59
▸ RECQL P46063 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ TSHR P16473 1/20 0.58
▸ ACHE P22303 2/20 0.56
▸ CCR3 P51677 1/20 0.54
▸ SIGMAR1 Q99720 1/20 0.53
▸ HRH3 Q9Y5N1 1/20 0.52
▸ L3MBTL3 Q96JM7 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL4962590 0.98 RECQL (0.58) DRD2DRD4DRD3RECQLSMN1; SMN2
Hydrochloric Acid SCHEMBL1610029 0.98 RECQL (0.58) DRD2DRD4DRD3RECQLSMN1; SMN2
SCHEMBL18868681 0.91 TSHR (0.53) DRD2DRD4DRD3RECQLSMN1; SMN2
SCHEMBL2202545 0.91 DRD4 (0.53) DRD2DRD4DRD3RECQLSMN1; SMN2
SCHEMBL2202542 0.91 DRD4 (0.53) DRD2DRD4DRD3RECQLSMN1; SMN2
SCHEMBL4275700 0.87 SIGMAR1 (0.58) DRD2DRD4DRD3RECQLSMN1; SMN2
SCHEMBL3709310 0.86 RECQL (0.70) DRD2DRD4DRD3RECQLSMN1; SMN2
SCHEMBL8192854 0.85 SIGMAR1 (0.50) DRD2DRD4DRD3SMN1; SMN2TSHR
Hydrochloric Acid SCHEMBL3706762 0.85 RECQL (0.68) DRD2DRD4DRD3RECQLSMN1; SMN2
SCHEMBL3285312 0.85 DRD2 (0.65) DRD2DRD4DRD3RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109311811-B Process for preparing 4- (piperidine-4-yl) morpholine 有机合成药品工业株式会社 2022-09-09 — — CN claimed
EP-3470394-B1 METHOD FOR PREPARING 4-(PIPERIDIN-4-YL)MORPHOLINE YUKI GOSEI YAKUHIN KOGYO KK (JP) 2022-01-26 — — EP claimed
US-20190210968-A1 METHOD FOR PREPARING 4-(PIPERIDIN-4-YL)MORPHOLINE YUKI GOSEI KOGYO CO., LTD. (JP) 2019-07-11 — — US claimed
EP-3470394-A1 METHOD FOR PRODUCING 4-(PIPERIDIN-4-YL)MORPHOLINE Yuki Gosei Kogyo Co., Ltd. (JP) 2019-04-17 — — EP claimed
CN-112986430-B Method for screening difference markers of Juansan milk powder and Holstein milk powder and application thereof 中国农业科学院农业质量标准与检测技术研究所 2022-09-16 — — CN disclosed
CN-109311811-B Process for preparing 4- (piperidine-4-yl) morpholine 有机合成药品工业株式会社 2022-09-09 — — CN disclosed
CN-109311811-B Process for preparing 4- (piperidine-4-yl) morpholine 有机合成药品工业株式会社 2022-09-09 — — CN disclosed
EP-3470394-B1 METHOD FOR PREPARING 4-(PIPERIDIN-4-YL)MORPHOLINE YUKI GOSEI YAKUHIN KOGYO KK (JP) 2022-01-26 — — EP disclosed
EP-3470394-B1 METHOD FOR PREPARING 4-(PIPERIDIN-4-YL)MORPHOLINE YUKI GOSEI YAKUHIN KOGYO KK (JP) 2022-01-26 — — EP disclosed
CN-110041302-B 2-amino-4-substituted pyridine derivative and synthesis method and application thereof 南方医科大学 2021-11-30 — — CN disclosed
CN-112986430-A Method for screening difference markers of Juansan milk powder and Holstein milk powder and application thereof 中国农业科学院农业质量标准与检测技术研究所 2021-06-18 — — CN disclosed
US-20190210968-A1 METHOD FOR PREPARING 4-(PIPERIDIN-4-YL)MORPHOLINE YUKI GOSEI KOGYO CO., LTD. (JP) 2019-07-11 — — US disclosed
US-20030130235-A1 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors SUGEN, INC. 2003-07-10 — — US disclosed
US-20030130280-A1 Treatment of acute myeloid leukemia with indolinone compounds SUGEN, INC. 2003-07-10 — — US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US disclosed
WO-2003035009-A2 TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS SUGEN, INC. (US) 2003-05-01 — — WO disclosed
WO-2003031438-A1 3-[4-(SUBSTITUTED HETEROCYCLYL)-PYRROL-2-YLMETHYLIDENE]-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2003-04-17 — — WO disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 — — US disclosed
WO-2002096361-A2 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. (US) 2002-12-05 — — WO disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190210968-A1 METHOD FOR PREPARING 4-(PIPERIDIN-4-YL)MORPHOLINE DNM1L, DNM2, DNM1 DRD2 235/4885DRD4 48/4885DRD3 438/4885
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 DRD2 3857/4885DRD4 3278/4885DRD3 3858/4885
US-20030130280-A1 Treatment of acute myeloid leukemia with indolinone compounds FLT3, FLI1, MCL1 DRD2 3214/4885DRD4 3490/4885DRD3 2812/4885
US-20030130235-A1 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors PDGFRB, PDGFRA, KDR DRD2 4101/4885DRD4 4375/4885DRD3 4208/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 DRD2 4563/4885DRD4 4659/4885DRD3 4388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.